SEngine Precision Medicine, a Seattle, Wash.-based oncology company, closed a $5.1m in Series A funding.
The round, which brings total funding to date to more than $9m, was led by the Bangarang Group with participation from various family offices and returning investors.
Founded in 2015, the company is a spin-off of the Fred Hutchinson Cancer Research Center, in Seattle, WA, founded to identify and develop the next generation of cancer targeted drugs.
Led by Dr. Carla Grandori, Founder and CEO, SEngine Precision Medicine is an oncology company accelerating cancer drug discovery through its CLIA certified, proprietary diagnostic platform PARIS®.
Its high-throughput screening technology simultaneously tests dozens of targeted anti-cancer agents against a patient’s unique cancer cells outside the body via patient-derived 3D tumor organoids. The results decode the most effective and least toxic treatment options in weeks. The AI-optimized platform leverages the aggregated, anonymized test results to develop new cancer-fighting drugs.
The PARIS® Test is currently utilized by oncologists throughout the United States to predict and validate personalized treatment options for their patients.